Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance

Ipsen reported strong year-to-date sales growth of 24.6% at constant exchange rates for the first nine months of 2026, with the core portfolio achieving 24.2% growth. The company upgraded its full-year 2026 guidance, projecting total sales growth around 23.0% at CER and core operating margin around 39.0%. The company strengthened its late-stage pipeline through acquisitions of Memo Therapeutics and Kartos Therapeutics, adding potravitug and navtemadlin, with multiple blockbuster-potential assets in Oncology, Rare Disease, and Neuroscience.